Participated · Series A · May 2026

Launched in 2020, CHOSEN develops dermatologist-designed topical formulations and nutraceuticals addressing pigmentation, skin texture, contour and hair aging. It operates a clinic-to-consumer model that integrates a B2B network of dermatologists with a direct-to-consumer platform, and reports insights from over 150,000 consultations. The company offers around 58 SKUs across doctor-led and D2C segments and its products are prescribed in more than 2,000 clinics nationwide. CHOSEN’s online channel serves customers across India, with nearly 95% of digital sales on its own platform and roughly 70% of revenue driven by repeat customers, primarily women aged 30–50. The company is preparing to expand into global skin-of-color markets in Latin America and East Asia and competes with brands such as Avène, Heliocare, Cetaphil, Sebamed, Shiseido and Dr. Sturm.

Participated · Equity · Oct 2025

Chando Group is a Chinese homegrown cosmetics brand that combines in-house raw material sourcing, research and development, and manufacturing with a fully digital operating system and efficient DTC distribution. The company manages multiple brands—including Chando, Perfection Research, Chunxia, Meisu, and Jichu—covering skincare, color cosmetics, personal care, men’s grooming, and baby care categories. Its R&D organization comprises 154 researchers with expertise spanning life sciences, material sciences, and applied chemistry. Chando has also partnered with medical institutions such as Huashan Hospital and the National Children’s Medical Center (Fudan University Children’s Hospital) to strengthen product innovation. The newly raised capital will be used to expand operations and support ongoing product development initiatives.

Led · Equity · Sep 2024

Abolis Biotechnologies, based in Évry-Courcouronnes, France, specializes in industrial solutions using microorganisms across food, healthcare, cosmetics and chemicals. The company combines expertise in biology, fermentation, IT, robotics, analytics and industrial property to develop bioproduction solutions. It leverages biotechnologies and micro-organisms to create economically and ecologically sustainable alternatives to petrochemical products and chemical ingredients. Abolis raised €35M in funding to support its growth. Backers included L’Oréal’s venture capital fund BOLD, DeepTech & Climate Fonds, and Evonik Venture Capital as lead investors, alongside Clay Capital, ICOS Capital and Liberset. The company intends to use the funds to accelerate expansion into global markets and to speed R&D to bring its own portfolio of ingredients, to be industrialized with partners, to market. The investment was accompanied by a new strategic industrial partnership between Abolis, L’Oréal and Evonik to bring selected innovations to market for the healthcare, cosmetic and chemical sectors. The company is led by CEO Cyrille Pauthenier.

Led · Series D · Jan 2024

Timeline (parent company Amazentis) is a Lausanne-based consumer health biotech focused on Mitopure®, a proprietary ingredient designed to improve mitochondrial function and support healthy aging. Mitopure® is backed by over 15 years of research, multiple clinical studies and more than 50 patents and is clinically proven to target a cellular longevity pathway. Timeline incorporates Mitopure® into next-generation nutritional supplements and topical skin health products. The company plans to expand its science, product categories, and markets across food, beauty, and health sectors and to build the brand in consumer longevity. Nestlé Health Science has been an investor since 2019. Timeline recently completed a significant financing to support these growth plans. Based in Lausanne, Switzerland, Amazentis develops products targeting mitochondrial health for advanced nutrition and pharmaceutical applications. Its proprietary lead product candidate, AMAZ-02, is an oral formulation of urolithin A that stimulates mitophagy to improve mitochondrial function in muscle. The company has reported preclinical results in Nature Medicine and presented Phase 1 clinical safety and translational data. Amazentis has established an extensive intellectual property portfolio and proprietary know‑how around urolithin A. With the recently completed Series C financing, the company plans to advance two pivotal Phase 2 trials (ENERGIZE and ATLAS) and to prepare for future commercial activities. The clinical program is focused on validating AMAZ-02 as a solution to support healthy aging and improve muscle function.

Participated · Equity · Aug 2023

VLGE builds V-Suite, a proprietary no-code world-builder and asset management platform that includes V-BLDR, a drag-and-drop design tool and templates for creators and brands. The company has opened applications for its SDK so creators and brands can build, upload assets, and create immersive virtual destinations. VLGE is targeting experience-driven industries—fashion, beauty, and art—with tools to create scalable, intuitive virtual experiences and explore monetization like NFTs. The startup positions its platform as more affordable and user-friendly than existing virtual-world platforms and aims to help brands reduce physical footprint while preserving cultural and storytelling roles. VLGE has raised $4 million in funding to date from investors that include Venrex VC and L’Oréal’s BOLD, and it lists advisers from Wave, Sandbox, and Paper Magazine. The company was launched by Evelyn Mora, a Finnish entrepreneur and sustainability strategist based in France.